Hola,
Are you new here?

BETACURE

financed

Personalized diagnosis and treatment of hyperinsulinemic hypoglycaemia caused by...

Personalized diagnosis and treatment of hyperinsulinemic hypoglycaemia caused by beta cell pathology Background: Hyperinsulinaemic hypoglycaemia (HH) is a potentially lethal disease caused by over functioning beta cells derived from the pancreatic islets of Langerhans. Lethal HH and brain damage is a problem especially in infants... see more

31/03/2018

STICHTING RADBOUD...

8M€

Project Budget: 8M€

Project leader

STICHTING RADBOUD UNIVERSITEIT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 16 Participantes

Financing granted El organismo FP7 notifico la concesión del proyecto The day 2018-03-31 We do not have the information of the call

0% 76% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

16 Participantes

STICHTING RADBOUD UNIVERSITE...

0.00€ | Leader

CONCENTRIS RESEARCH MANAGEME...

N.D. | participant

UNIVERSITY OF TURKU

N.D. | participant

KANTONSSPITAL BASEL

N.D. | participant

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project leader

STICHTING RADBOUD UNIVERSITEIT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Project Budget 8M€

participation deadline Sin fecha límite de participación.

Project description Background: Hyperinsulinaemic hypoglycaemia (HH) is a potentially lethal disease caused by over functioning beta cells derived from the pancreatic islets of Langerhans. Lethal HH and brain damage is a problem especially in infants with congenital HH. Current therapeutic approaches are associated with severe side effects/morbidity (diabetes, exocrine pancreas insufficiency etc.) considered acceptable in relation to the lethal outcome of HH although massively reducing quality of life and also life expectancy. Aims and objectives: In order to significantly improve therapy of this awful disorder, we propose to develop a simultaneous imaging/therapy platform allowing diagnostic imaging as well as image guided surgical, photodynamic or radiopeptide therapy to selectively resect/destroy diseased beta cells. This platform will enable delivery of patient-individual tailored therapy, increasing cure rate while significantly reducing or even avoiding side effects. The platform will integrate information from pre-clinical imaging for optimal therapy planning with intra-operative imaging for image guided surgery. By implementation of extended field optical coherence tomography, information on a histopathological level will allow increased precision of therapy. Highly innovative photodynamic therapy will enable selective (endoscopic) destruction of diseased beta cells without resection of pancreatic tissue. Outcome: Our highly-innovative integrated imaging/therapy (theranostic) platform will allow diagnosis and monitoring of disease, support and guide therapeutic intervention, predict outcome of intervention and individual prognosis. This technology will massively improve therapy, especially in infants, by improving cure rates while significantly reducing morbidity for improved quality of life and increased life expectancy. We will contribute to the goals of the International Rare Diseases Research Consortium (IRDiRC): 200 new therapies.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers